Anti-neoplastic essential medicines | % Retail pharmacies (n=32) | % Private hospital pharmacies (n=3) | % Public hospital pharmacies (n=4) | % Survey anchor areas (n=7) |
Asparaginase, powder inj, 10 000 IU in vial | 19 | 100 | 100 | 100 |
Bleomycin, powder inj, 15 mg | 53 | 100 | 75 | 100 |
Carboplatin, inj, 150 mg/15 mL | 47 | 100 | 50 | 100 |
Carboplatin, inj, 450 mg/45 mL | 44 | 100 | 50 | 86 |
Carboplatin, inj, 50 mg/5 mL | 0 | 0 | 0 | 0 |
Carboplatin, inj, 600 mg/60 mL | 0 | 0 | 0 | 0 |
Carboplatin—no specific strength | 47 | 100 | 75 | 100 |
Cisplatin, inj, 100 mg/100 mL | 0 | 0 | 0 | 0 |
Cisplatin, inj, 50 mg/50 mL | 44 | 100 | 75 | 100 |
Cisplatin—no specific strength | 44 | 100 | 75 | 100 |
Cyclophosphamide, powder inj, 500 mg in vial | 47 | 100 | 0 | 86 |
Cyclophosphamide, tab, 25 mg | 0 | 0 | 0 | 0 |
Cytarabine, powder inj, 100 mg in vial | 31 | 100 | 75 | 86 |
Dacarbazine, powder inj, 100 mg in vial | 16 | 0 | 50 | 29 |
Dactinomycin, powder inj, 500 µg in vial | 28 | 100 | 25 | 57 |
Daunorubicin, powder inj, 50 mg in vial | 0 | 0 | 0 | 0 |
Dexamethasone, oral liquid, 2 mg/5 mL | 0 | 0 | 0 | 0 |
Doxorubicin, powder inj, 10 mg | 31 | 100 | 50 | 86 |
Doxorubicin, powder inj, 50 mg | 47 | 100 | 75 | 100 |
Doxorubicin—no specific strength | 47 | 100 | 75 | 100 |
Etoposide, cap, 100 mg | 0 | 0 | 0 | 0 |
Etoposide, inj, 100 mg | 38 | 67 | 50 | 100 |
Ifosfamide, powder inj, 500 mg | 0 | 0 | 0 | 0 |
Ifosfamide, powder inj, 2 g vial | 19 | 67 | 0 | 57 |
Ifosfamide, powder inj, 1 g | 28 | 67 | 50 | 86 |
Ifosfamide, powder inj—no specific strength | 34 | 67 | 50 | 88 |
Mercaptopurine, tab, 50 mg | 56 | 100 | 25 | 100 |
Methotrexate, powder inj, 50 mg in vial | 78 | 100 | 75 | 100 |
Methotrexate, tab, 2.5 mg | 84 | 67 | 75 | 100 |
Paclitaxel, powder inj, 6 mg/mL | 16 | 100 | 0 | 57 |
Prednisolone, oral liquid, 5 mg/mL | 88 | 100 | 25 | 100 |
Prednisolone, tab, 25 mg | 0 | 0 | 0 | 0 |
Prednisolone, tab, 5 mg | 91 | 100 | 75 | 100 |
Prednisolone, tab—no specific strength | 91 | 100 | 75 | 100 |
Thioguanine, solid oral dosage form, 40 mg | 34 | 67 | 25 | 43 |
Vinblastine, powder inj, 10 mg (sulfate) in vial | 41 | 100 | 50 | 100 |
Vincristine, powder inj, 1 mg | 47 | 100 | 75 | 100 |
Vincristine, powder inj, 5 mg | 0 | 0 | 0 | 0 |
Vincristine, powder inj—no specific strength | 47 | 100 | 75 | 100 |
Mean (SD) | 38(28) | 71(42) | 43(33) | 70(41) |
Non-canceressential medicines | ||||
Amoxicillin 250 mg, cap/tab | 84 | 0 | 50 | 100 |
Ciprofloxacin 500 mg, cap/tab | 100 | 100 | 50 | 100 |
Metformin 500 mg, cap/tab | 100 | 67 | 100 | 100 |
Omeprazole 20 mg, cap/tab | 100 | 67 | 75 | 100 |
Mean (SD) | 96(8) | 58(42) | 69(24) | 100 |
Mean percentages were calculated using all specific strengths, except six which had more than one strength, hence were instead calculated as ‘no specific strength’.
cap, capsule; inj, injection; tab, tablet.